All lobbying filings

S-3 GROUP

Lobbying for VIATRIS (MYLAN, INC) · Generics and specialty pharmaceutical company

Filing 1st Quarter - Amendment

1st Quarter (Jan 1 - Mar 31) 2025 · Pennsylvania · House · Senate · $60,000.00 income · posted Apr 21, 2025

Official filing document

Bills named in this filing 2

S 1302
Increasing Transparency in Generic Drug Applications Act
HR 1843
To amend the Federal Food, Drug, and Cosmetic Act to increase transparency in generic drug applications.

Lobbying activity 1

Health Issues

Issues related to drug pricing; pharmaceutical supply chain; modernization of prescribing information for physicians and pharmacists; Increasing Transparency in Generic Drug Applications, S.1302 and H.R. 1843; Part D Formulary Design and Generic Drug Testing

Source: federal Lobbying Disclosure Act filing. Bills are parsed from the activity descriptions.